Literature DB >> 32413460

Optimizing neuromelanin contrast in the substantia nigra and locus coeruleus using a magnetization transfer contrast prepared 3D gradient recalled echo sequence.

Yu Liu1, Junchen Li2, Naying He1, Yongsheng Chen3, Zhijia Jin1, Fuhua Yan4, E Mark Haacke5.   

Abstract

Neuromelanin (NM) loss in the substantia nigra (SN) and locus coeruleus (LC) is being investigated as an imaging biomarker for Parkinson's disease (PD) using magnetization transfer contrast (MTC) magnetic resonance imaging. The MTC pulse operates in a way to suppress tissue with high macromolecular content thereby highlighting the presence of NM in the LC and the SN. The MTC pulse also leads to a reduction in the effective T1 of the tissue. In the past, a 3D gradient echo (GRE) sequence has usually been run with a single flip angle (FA) generally to highlight the T1 shortening effect when trying to visualize NM. We contend that the NM will be best seen with a low FA (relative to the Ernst angle) because the NM has high water content relative to the surrounding tissues. Therefore, the goal of this paper was to optimize the NM contrast in the SN and LC as a function of flip angle using a 3D GRE MTC strategically acquired gradient echo (STAGE) imaging approach. In order to accomplish this, short repeat time (62 ​ms), 3D GRE imaging data were collected for 7 different flip angles ranging from 5° to 40° for 14 healthy volunteers (age range 24-43 years, mean ​± ​SD ​= ​34.8 ​± ​6.0 years, 6 males). By measuring the contrast-to-noise ratio between these structures and the surrounding tissues, we found that the FA showing the best NM contrast was 15° - 20° for the SN and 20° - 25° for the LC. Using STAGE imaging with just two flip angles (15° and 30°) made it possible to quantify not only tissue properties such as T1 and proton density but also to generate synthetic MTC images at an arbitrary FA. These synthetic images make it possible to optimize the contrast for any changes in tissue property that might occur in the LC or SN as a function of age or disease. In conclusion, practically, two scans could be collected in roughly 7 ​min each for both FAs in a standard clinical imaging setting to evaluate the signal intensity and volume of the NM in the LC and SN.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Magnetization transfer contrast; Neuromelanin; Parkinson’s disease; Quantitative MRI; STAGE imaging

Mesh:

Substances:

Year:  2020        PMID: 32413460     DOI: 10.1016/j.neuroimage.2020.116935

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  4 in total

1.  Acceleration of neuromelanin-sensitive MRI sequences in the substantia nigra using standard MRI options.

Authors:  Marieke van der Pluijm; Elon D Wallert; Bram F Coolen; Kaithlyn T Tjong Tjin Joe; Lieuwe de Haan; Jan Booij; Elsmarieke van de Giessen
Journal:  Neuroradiology       Date:  2022-09-28       Impact factor: 2.995

2.  Proton Magnetic Resonance Spectroscopy for the Early Diagnosis of Parkinson Disease in the Substantia Nigra and Globus Pallidus: A Meta-Analysis With Trial Sequential Analysis.

Authors:  Wenbin Gu; Chen He; Juping Chen; Junchen Li
Journal:  Front Neurol       Date:  2022-06-16       Impact factor: 4.086

3.  Reliability and Reproducibility of Neuromelanin-Sensitive Imaging of the Substantia Nigra: A Comparison of Three Different Sequences.

Authors:  Marieke van der Pluijm; Clifford Cassidy; Melissa Zandstra; Elon Wallert; Kora de Bruin; Jan Booij; Lieuwe de Haan; Guillermo Horga; Elsmarieke van de Giessen
Journal:  J Magn Reson Imaging       Date:  2020-10-09       Impact factor: 4.813

4.  Automatic detection of neuromelanin and iron in the midbrain nuclei using a magnetic resonance imaging-based brain template.

Authors:  Zhijia Jin; Ying Wang; Mojtaba Jokar; Yan Li; Zenghui Cheng; Yu Liu; Rongbiao Tang; Xiaofeng Shi; Youmin Zhang; Jihua Min; Fangtao Liu; Naying He; Fuhua Yan; Ewart Mark Haacke
Journal:  Hum Brain Mapp       Date:  2022-01-24       Impact factor: 5.038

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.